| Literature DB >> 35860502 |
Mohammadarian Akbari1, Reyhane Eghtedarian2, Bashdar Mahmud Hussen3,4, Solat Eslami5,6, Mohammad Taheri7, Seyedeh Morvarid Neishabouri8, Soudeh Ghafouri-Fard9.
Abstract
Dysfunction of regulatory T cells (Tregs) has been shown to affect the etiology of autism spectrum disorder (ASD). Differentiation of this group of T cells has been found to be regulated by a group of long non-coding RNAs (lncRNAs). In this study, we have examined the expression of five lncRNAs that regulate this process in the blood samples of ASD cases compared with controls. These lncRNAs were FOXP3 regulating long intergenic non-coding RNA (FLICR), MAF transcriptional regulator RNA (MAFTRR), NEST (IFNG-AS1), RNA component of mitochondrial RNA processing endoribonuclease (RMRP), and Th2 cytokine locus control region (TH2-LCR). Expression of RMRP was significantly lower in total ASD cases compared to controls [expression ratio (95% CI) = 0.11 (0.08-0.18), adjusted P-value < 0.0001]. This pattern was also detected in both men and women cases compared with corresponding controls [expression ratio (95% CI) = 0.15 (0.08-0.29) and 0.08 (0.03-0.2), respectively]. Likewise, expression of NEST was reduced in total cases and cases among men and women compared with corresponding controls [expression ratio (95% CI) = 0.2 (0.14-0.28); 0.22 (0.12-0.37); and 0.19 (0.09-0.43), respectively; adjusted P-value < 0.0001]. Lastly, FLICR was downregulated in total cases and cases among both boys and girls compared with matched controls [expression ratio (95% CI) = 0.1 (0.06-0.19); 0.19 (0.08-0.46); and 0.06 (0.01-0.21), respectively; adjusted P-value < 0.0001]. These three lncRNAs had appropriate diagnostic power for differentiation of ASD cases from controls. Cumulatively, our study supports dysregulation of Treg-related lncRNAs in patients with ASD and suggests these lncRNAs as proper peripheral markers for ASD.Entities:
Keywords: ASD; FLICR; MAFTRR; NEST; RMRP; TH2-LCR
Year: 2022 PMID: 35860502 PMCID: PMC9289514 DOI: 10.3389/fnmol.2022.939224
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 6.261
Primer sequences.
| Gene | Sequence 5 → 3 | Primer length (bp) |
|
| F-AGATGAGTATGCCTGCCGTG | 20 |
| R-GCGGCATCTTCAAACCTCCA | 20 | |
|
| F-GGG CTT TTC CAG AAG GGT CT | 20 |
| R-AGC CCA GGG TTC TAG TCG | 18 | |
|
| F-CTG AAG GGA CAG GAC GGA CAA C | 22 |
| R-GGG GAA AAC CTG GAA AGA GGG A | 22 | |
|
| F-AGC TGA TGG CAA TCT | 21 |
| R-TGA CTT CTC CAG CGT TTT | 21 | |
|
| F-GTA GAC ATT CCC CGC TTC CCA | 21 |
| R-GAG AAT GAG CCC CGT GTG GTT | 21 | |
|
| F-GCT CCC CAG GCT TTT GAG ATA | 21 |
| R-TGG TGA TGC TGA AGG GAG AC | 20 |
General demographic data of enrolled cases and controls.
| Study groups | Parameters | Values | |
| Patients | Sex (number) | Male | 19 |
| Female | 11 | ||
| Age (years, mean ± SD) | Male | 6 ± 1.33 | |
| Female | 6 ± 1.73 | ||
| Controls | Sex (number) | Male | 30 |
| Female | 11 | ||
| Age (years, mean ± SD) | Male | 6.2 ± 1.88 | |
| Female | 5.63 ± 1.28 | ||
FIGURE 1Relative expressions of five Treg-related genes RMRP, TH2LCR, NEST, and FLICR genes in patients with ASD (total) and healthy controls (total) as designated by –delta Ct values. –Delta Ct data were plotted as box and whisker plots. Median, mean, and interquartile ranges are shown. Unpaired t-test or non-parametric test (Mann–Whitney U test) was used to identify differentially expressed genes between two groups (****P-value < 0.0001; ns, non-significant).
FIGURE 2Relative expression levels of five Treg-related genes in subgroups of patients with ASD vs. control subgroups as described by –delta Ct values. –Delta Ct data is plotted. Median, mean, and interquartile ranges are shown. The effects of disease and gender on the expression of lncRNAs were appraised using two-way ANOVA and Tukey post hoc tests (****P-value < 0.0001; ns, non-significant).
The results of the expression study of five Treg-related genes in peripheral blood of patients with ASD compared with healthy controls (&, adjusted P-value, RE, expression ratio).
| Studied genes | Total patients vs. total controls (30 vs. 41) | Male patients vs. normal males (19 vs. 30) | Female patients vs. normal females (11 vs. 11) | |
| RMRP | ER (95% CI) | 0.11 (0.08–0.18) | 0.15 (0.08–0.29) | 0.08 (0.03–0.2) |
| P& | <0.0001 | <0.0001 | <0.0001 | |
| TH2LCR | ER (95% CI) | 1.23 (0.7–2.24) | 1.2 (0.47–3.34) | 1.29 (0.31–5.27) |
| P& | 0.47 | 0.91 | 0.96 | |
| NEST | ER (95% CI) | 0.2 (0.14–0.28) | 0.22 (0.12–0.37) | 0.19 (0.09–0.43) |
| P& | <0.0001 | <0.0001 | <0.0001 | |
| FLICR | ER (95% CI) | 0.1 (0.06–0.19) | 0.19 (0.08–0.46) | 0.06 (0.01–0.21) |
| P& | <0.0001 | <0.0001 | <0.0001 | |
| MAFTRR | ER (95% CI) | 0.78 (0.35–1.8) | 0.68 (0.18–2.54) | 1.67 (0.24–11.3) |
| P& | 0.49 | 0.87 | 0.89 | |
*P-value at a significance level of P < 0.05.
Spearman’s correlations between transcript levels among the patients with ASD (N = 30) and healthy controls (N = 41).
| TH2LCR | NEST | FLICR | MAFTRR | |||||
| Patients | Control | Patients | Control | Patients | Control | Patients | Control | |
| RMRP | 0.31 | 0.7 | 0.46 | 0.62 | 0.54 | −0.2 | 0.17 | 0.61 |
| TH2LCR | 0.08 | 0.53 | 0.65 | −0.18 | 0.71 | 0.66 | ||
| NEST | 0.39 | −0.3 | 0.2 | 0.45 | ||||
| FLICR | 0.61 | −0.06 | ||||||
*P-value at a significance level of P < 0.05.
**P-value at a significance level of P < 0.001.
FIGURE 3Receiver operating characteristic curves of RMRP, IFNG-AS1, and FLICR lncRNAs transcript levels show their diagnostic power in the differentiation of total ASD cases from controls.
The results of ROC curve analysis in total patients with ASD as well as sex-based subgroups.
| RMRP | NEST | FLICR | ||||||||||
| AUC ± SD | Sensitivity | Specificity | AUC ± SD | Sensitivity | Specificity | AUC ± SD | Sensitivity | Specificity | ||||
| Total patients vs. total normal controls (30 vs. 41) | 0.97 ± 0.01 | 0.97 | 0.88 | <0.0001 | 0.96 ± 0.02 | 0.96 | 0.85 | <0.0001 | 0.89 ± 0.04 | 0.77 | 0.93 | <0.0001 |
| Female patients vs. female normal controls (11 vs. 11) | 1 ± 0.00 | 1 | 1 | <0.0001 | 0.9 ± 0.07 | 0.9 | 0.9 | 0.001 | 0.93 ± 0.05 | 0.81 | 1 | 0.0006 |
| Male patients vs. male normal controls (18 vs. 30) | 0.97 ± 0.02 | 0.95 | 0.93 | <0.0001 | 0.97 ± 0.01 | 0.95 | 0.9 | <0.0001 | 0.86 ± 0.06 | 0.74 | 0.93 | <0.0001 |